Zentalis Pharmaceuticals (ZNTL) Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at AACR

March 10, 2021 4:37 PM EST
Get Alerts ZNTL Hot Sheet
Price: $50.84 -0.49%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that three abstracts have been accepted for presentation, including a late-breaker on its WEE1 inhibitor, ZN-c3, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021. The meeting will be held virtually on April 10-15 and May 17-21, 2021.

“The important data we are presenting at AACR supports the ability of our Integrated Discovery Engine to develop differentiated oncology therapeutic candidates across diverse cancer targets and types,” commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis Pharmaceuticals. “We especially look forward to presenting clinical data from our ongoing Phase 1 monotherapy trial of our WEE1 inhibitor, ZN-c3, selected for a late-breaking session. In addition, results from two cell-based studies of ZN-c3, and our EGFR inhibitor, ZN-e4, demonstrated impressive selectivity and tolerability, which we believe positions these candidates to improve upon the constraints of existing products.”

Late-Breaker Oral Presentation:

Title: Clinical activity of a single-agent ZN-c3, an oral WEE1 inhibitor, in a Phase 1 dose-escalation trial in patients with advanced solid tumors Session: Early Clinical Trials with New Anticancer Agents Presentation Number: CT016 Date/Time: Saturday, April 10, 2021 at 1:30 p.m. EDT

Poster Presentations:

Title: Discovery of ZN-c3, a potent Wee-1 inhibitor with a differentiated pharmacologic and kinase selectivity profile Session: Molecular and Cellular Biology / GeneticsAbstract ID: 1965Date/Time: Available starting on Saturday, April 10, 2021 at 8:30 a.m. EDT

Title: Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer Session: Oncogene Growth Factors and their ReceptorsAbstract ID: 2423Date/Time: Available starting on Saturday, April 10, 2021 at 8:30 a.m. EDT

The poster presentation abstracts are currently available on the AACR Annual Meeting 2021 website at www.aacr.org/meeting/aacr-annual-meeting-2021/.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

Twitter